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People with epilepsy plus learning disabilities pose a challenge in terms of clinical management and research investigation, 
and, to date, the measurement of outcomes in this population has been limited. There have been uncertainties concerning both 
the ‘what’ and the ‘how’ of assessment. This paper presents a comprehensive review of available outcome measures across 
nine domains, i.e. relating to seizures, drugs, cognitive function, behaviour, social functioning, carer functioning, attitudes, 
motivation and ‘quality of life’. This last domain reflects more global measures designed to encompass several assessment 
strands. The uses and limitations of each scale is discussed and, where data are available, psychometric properties are also 
presented. The paper concludes with suggestions for the further development of outcome measures in this population. 
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INTRODUCTION 
Kerr and Espie’ have highlighted the importance of 
valid and reliable measurement of therapeutic out- 
comes in people who have epilepsy plus learning dis- 
ability. This paper has four aims which flow logically 
from the conceptual base already provided by Kerr 
and Espie. These can best be stated in the form of 
questions. 
First, what are the domains of measurement which 
are appropriate to target in this population? Secondly, 
what measurement criteria, both psychometric and 
practical, have to be met? Thirdly, are there existing 
measures, or ones in development or common usage, 
which fit the bill? Finally, what are the implications 
for current clinical practice and for priority research 
development? 
This paper is based upon a ‘round-table discussion’ 
amongst the authors, which took place at a recent ma- 
jor scientific meeting. It represents our pooled knowl- 
edge and experience and is intended to provide a po- 
sition statement on current good practice and future 
direction. 
WHAT SHOULD WE MEASURE AS OUTCOME 
VARIABLES? 
Nine possible domains of measurement arise and are 
worthy of consideration. These are described in the 
first column of Table 1. 
Traditionally, the ictus and the immediate pre- and 
post-ictal period have been the focus of concern in 
This paper summarizes a round-table discussion which took place at the Second European Congress of Epileptology, The Hague, the 
Netherlands. in September 1996. The meeting was supported by an unrestricted educational grant from Janssen-Cilag Ltd. PO Box 79, 
Saunderton, High Wycombe, Buckinghamshire, HP14 4HJ, England, UK. 
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Table 1: Available assessment measures across domains of functioning and incorporating psychometric properties of scales. 
Domain Scale References Psychometric or other data 
Seizures (type, ILAE 24 International *standard’. Interobserver agreement variable. 
frequency, 
panem. 
intrusiveness) 
Drugs (effects, 
side-effects, 
etc.) 
Cognitive 
function 
(attention, 
memory, 
abilities) 
classification 
Concerted 
Action Family 
Data protocol 
Seizure charts 
Seizure diaries 
Videotape 
recordings 
Video telemetry 
Behavioural 
analysis 
Liverpool 
Seizure Severity 
Scales 
Drug profiles 
(specific drug) 
Drug profiles 
(general) 
Adverse Events 
Profile 
Leeds 
Psychomotor 
Test (adapted) 
Wechsler Adult 
Intelligence 
Scale (Revised; 
UK) 
Wechsler 
Memory Scale 
(Revised) 
Rivermead 
Behavioural 
Memory Test 
British Abilities 
Scales 
Corsi Tests 36 
F. Elmsley 
(pers. comm.) 
Locally derived 
Industry 
2 
2. 25 
Standard 
clinical 
procedure 
77 
21. 23 
Pharmaceutical 
industry 
Hospital 
pharmacists 
Locally derived 
31 
Espie et al 
(pers. comm.) 
32 
33 
34 
35 
May improve diagnostic agreement. As yet unproven. 
Common usage. High face validity. Yield seizure frequency data. Few 
psychometric data. May be unreliable. Quick to complete. 
More verifiable than seizure charts. Do not require carers/observers to 
make clinical judgement. Otherwise similar. 
Very useful for differential diagnosis. May be problems in capturing 
events. No formal studies. Time-consuming. 
As above. Has been systematically studied. Video + EEG improves 
diagnostic confidence. Requires compliant patients. Not portable. 
Common usage. Good validity. Yields contextual information. May be 
time-consuming for carers. Quick to review. 
Test-retest 0.79 for ‘percept’ and 0.80 for ‘ictal’. Internal 
consistency 0.69 and 0.85 respectively. Ictal scale can differentiate 
seizure types. Frequency and severity of seizures independent. Has been 
adapted for learning disability with acceptable levels of internal 
consistency for seizure severity. mood and behaviour scales 
(alpha = 0.7-0.8). 
Thorough specifications. Useful to devise checklist. Objective signs 
measurable. Carer cannot report experimential symptoms. Allow 5 mins 
to review. 
May be incorporated into routine practice. Some overlap in common 
side-effects but also specifics (above). Communication problems (as 
above). Also quick. 
Now adapted for completion by carer rather than patient. Psychometric 
data awaited. 
Simplified version of Leeds Test. Two-choice reaction time task. 
Generates data on correct, incorrect and non-responses. Requires several 
trials to train subjects to task. Takes IO trials to measure baseline (allow 
40 ms total). 
Standardized on general population with mean IQ of 100. Very good 
psychometric properties (test-retest range by sub-test from 0.67 to 0.94 
with Full Scale IQ 0.96; internal consistency range 0.68 to 0.89 with 
FSIQ 0.97). WAIS is accepted criterion scale for IQ. Not recommended 
for patients with IQ < 60 as it loses its measurement 
sensitivity/discrimination. May require two assessment sessions. Allow 
up to 90 mins in total. 
Standardization as with WAIS. Reliability coefficients 0.70-0.90 across 
five subsets with test-retest 0.80-0.93. Also not recommended except in 
borderline/mild learning disability. May require two assessment sessions. 
Allow up to 75 mins. 
Validated on patients with acquired brain damage: not people with 
learning disability. Strong psychometric properties-alternate forms 
reliability of 0.85 for the profile score; 100% concordance between raters 
for scoring categorization. Four parallel versions permit repeat testing. 
Only suitable for people with mild intellectual disability. Allow 60 mins. 
Standardized on British children. Internal consistency range 0.45-0.9 I. 
Will prove sensitive in measurement down to mental age of around 
3 years. Not validated specifically on adults with learning disabilities. As 
with WAIS can profile across range of cognitive functions. May require 
two assessment sessions. Allow up to 90 mins. 
Two shon-term memory tasks, one spatial and one verbal, in the form of 
a computer game. Left-sided epileptic discharges primarily affect the 
verbal task and right-sided discharges affect the spatial task. Not 
specifically validated for people with learning disabilities. 
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Table 1: (Continued.) 
Domain Scale References Psychometric or other data 
FePsy 38 Normative data by age group and by sex for the normal population and 
Neurotoxity 
Scale 
Visual Analogue 
Scales 
Behavior State 
Analysis 
Behavioural 
adjustment 
(behaviour, psy- 
chopathology) 
Psychopathology 
instrument for 
Mentally 
Retarded Adults 
PASSAD 
Aberrant 
Behavior 
Checklist 
Psychosocial 
Behaviour Scale 
39.40 
Locally derived 
41-43 
44 
Hester Adrian 
Research 
Centre, 
Manchester 
(1994) 
45. 78, 79 
46 
Adaptive 42. 80 
Behavior 
Scales-Part Two 
Attention 
Deficit 
Disorder- 
Hyperactivity 
Questionnaire 
Society for the 
Study of 
Behavioural 
Phenotypes 
(SSBP) Postal 
Questionnaire 
48 
50 
for people with epilepsy. Auditory and visual reaction time and binary 
choice reaction time tasks, rhythm test, vigilance test. Good 
psychometric properties. Task instructions require some computer 
experience/training. Not recommended for people with moderate to 
severe learning disabilities. 
Good evidence of face and content validity and growing body of 
evidence on reliability. Scale was able to differentiate between volunteer 
subjects administered benzodiazepine vs. placebo. Currently being used 
in several international multicentre trials. 
Easy to administer. Can be ‘tailored’ to the patient and may be used as a 
repeated measure. Few psychometric data. Modest correlations with 
Leeds adapted (above) for ratings of ‘concentration’ (0.55-0.60). 5 mins 
to complete. 
Interrater concordance variable for occurrence of specific states in 
different studies (range 58-92%). Observationally based and potentially 
verifiable procedure. Time-consuming for training of raters, and for 
application. 
Alpha coefficient of 0.85 (internal consistency) and 0.91 for test-retest, 
for the informant version of the scale. Self-report version has less 
favourable psychometric properties. Validational work 
demonstrates 87.9% concordance between informant version and 
DSM-III axis I diagnosis. Factor analysis produced nine factors, many of 
which parallel psychiatric diagnoses. Useful screening tool for research. 
Allow 45 mins. 
A diagnostic tool for psychiatric illness/psychopathology in people with 
learning disabilities. A short-form screening tool has also been 
developed. 
Widely used measure of behavioural problems. Factor structure from 
original New Zealand study replicated in UK. Robust internal 
consistency (range 0.86-0.92) and acceptable interrater reliability (0.63). 
Test-retest reliability is very high (> 0.95). Criterion validation limited 
(e.g. with ABS-Part Two), perhaps reflecting problems with the latter 
measure. Valid as measure of treatment-related change. Allow 15 mins. 
Content validation based on its specific development for people with 
learning disabilities plus epilepsy. Recommended in relation to 
non-epileptic seizure disorders. Factorially sound structure. Interrater and 
test-retest data not available. High internal consistency (mean alpha 
of 0.81 (0.63-0.93); mean corrected alpha if item deleted 0.92 
(0.91-0.93)). Unpublished criterion validation of 0.68 with ABC 
(II = 96). Allow 10 mins. 
Standardization sample North American. Published by American 
Association on Mental Retardation. Criticized as not measuring severity 
(compared to frequency) of problem behaviours. Interrater reliability 
modest (0.57) as is agreement/disagreement concerning frequency of 
occurrence of target behaviours (range 0.37-0.77). Allow 40 mins. 
English translation available from the first author. Measures attention 
deficit in children. Some validational work in relation to the Connors 
Classroom Rating Scale. No published data on people with epilepsy. 
May be useful screen for developmental disorders of attentional deficit 
and impulsivity. Allow IO mins. 
Produced for research purposes by SSBP. Child and adult versions 
available. Test-retest reliability utilising kappa and weighted kappa 
highly satifactory for structured items. 
Zung Self-rating 54 
Anxiety 
Standard administration has no psychometric justification in people with 
learning disabilities. Simplified yes/no version of the scale improves 
split-half and test-retest correlations to 0.49 and 0.83 respectively. 
Suitable for mild to moderate learning disabilities. 20 items. Allow 
10 mins. 
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Table 1: (Continued.) 
Domain Scale References Psychometric or other data 
Social Washington 55 Extensive validational basis internationally on people with epilepsy. Not 
functioning 
(independence, 
life skills, work. 
etc.) 
Carer 
functioning 
(psychopathol- 
ogy. burden. 
strain) 
Attitudes/ 
motivation 
(knowledge, 
attributions, 
compliance, 
coping skills) 
Psychosocial 
Seizure 
Inventory 
Vineland 
Adaptive 
Behavior Scales 
Adaptive 
Behavior 
Scales-Part One 
Lidcombe 
Psychosocial 
Disability Scale 
Hospital 
Anxiety and 
Depression 
Scale 
Beck 
Depression 
Scale 
General Health 
Questionnaire 
Index of 
Psychological 
Well-being 
Burden 
Inventory 
(modified) 
Caregiver Strain 
Impact of 
Epilepsy Scale 
Epilepsy 
Knowledge 
Profiles 
Epilepsy 
Knowledge 
Profile (adapted) 
Clinic data on 
attendance etc. 
Rosenbaum 
Self-Control 
Schedule 
Rosenbaum 
Self-Control 
Schedule 
(adapted) 
56 
41 
57 
59 
60 
61 
62 
63 
65 
66 
67. 82 
68 
Locally derived 
69 
70 
validated for people with learning disabilities. Face validity in this 
population is poor except for borderline/mild categories. 
Widely used. Norms for residential and community samples of people 
with learning disabilities. Useful sub-scales on ‘Daily Living Skills’ 
(personal, domestic and community). Internal consistency (0.99). 
test-retest (0.85). interrater reliability (0.72). Other sub-scales more 
‘culture bound’. 60 years of research study. Ample evidence of construct 
and content validation; criterion validated against other scales. Allow 
60 mins. 
Widely used. ABS-Part Two concerns adaptive behaviours, i.e. 
independence skills etc. Reasonable psychometric properties. Mean 
interrater reliability of 0.86 (range across sub-scales 0.71-0.77). Limited 
validational work. Allow 60 mins. 
A head injury outcome scale which has been adapted by Clark for use 
with people who develop epilepsy. Validated against Glasgow Outcome 
Scale. Only nine items. Quick to complete. Not specifically used in a 
learning-disabilities setting. 
Criterion validated ‘cut-off points for anxiety (0.74) and depression 
(0.70) for severity compared with psychiatric ratings. Item-total 
correlations for anxiety (0.41-0.76) and depression (0.30-0.60) 
suggesting satisfactory internal consistency. Allow IO mins. 
Extensive psychometric evaluation. Mean alpha (internal consistency) 
0.86 in psychiatric populations. Greater stability of scores in 
non-psychiatric populations (0.60-0.90 test-retest). Sound content 
validation (mean of 0.72) against other scales. Allow 15 mins. 
Widely used for population screening purposes. Several forms of varying 
length. Has validated cut-off scores. 
Designed as mail-out questionnaire for population screening. Validated 
on this basis. Strong concordance with psychiatric ratings/neurotic 
indices. Only eight items, 3 mins. 
Content areas derived from carers. Limited psychometric data: none in 
relation to people with learning disabilities. Inverse relationships 
between ‘burden’ and contact with impaired person. Allow IO mins. 
Not validated on people with learning disabilities. In original studies 
demonstrated good internal consistency (0.86) and good content. 
validation compared with carers’ perceptions of stress factors. Allow 
IO mins. 
Based on experience of working with children with epilepsy and 
families. Appears valid. Not formally studied in psychometric terms. 
Allow I5 mins. 
Extensive content validation of ‘general knowledge’ of questionnaire. 
Good ‘readibility’ index. Test-retest (0.684.88) and alpha reliability 
(0.49-0.63). Has measurement sensitivity. Clear scoring criteria. Allow 
IO mins for general-knowledge version. ‘Knowledge of own condition’ 
scale also IO mins but answers require verification from clinical sources. 
Preliminary mainly descriptive work with people with learning 
disabilities suggests possibilities of use within mild learning disability. 
Many services collect default/cancellation or other data relevant to 
compliance. This may be part of audit. 
Mean alpha of 0.81 for internal consistency and test-retest reliability 
of 0.86. Validated against other self-control/cognition tests. Validated 
also with people who have epilepsy. Too complex for people with 
learning disabilities. Allow 30 mins even for able subjects. 
Adaptation of the above to only six items. Correlates 0.94 with full 
version of the Self-control Schedule. Yields two-factor solution in people 
with chronic epilepsy. Allow 5 mins. 
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Table 1: (Continued.) 
Domain Scale References Psychometric or other data 
Adolescent 71 Eighteen-item short-form version correlates > 0.75 with full scale. 
Coping Scale Validated with secondary-school students of normal abilities. Of limited 
applicability for people with significant learning disabilities. 
Global measures Epilepsy and 
(quality of life) Learning 
Disability 
Quality of Life 
Scale 
Epilepsy 
Outcome Scale 
Health of the 
Nation Outcome 
Scale (learning 
disabilities) 
53,74 
Espie er a/ in 
press 
For completion by parents/informal carers of children with epilepsy and 
learning disabilities. Yields scores on three sub-scales and single items 
relating to seizure-related injury, overall health and quality of life. 
Internal consistency by coefficient alpha ranges from 0.71 to 0.84. 
Test-retest for seizure severity (0.84). behaviour (0.87) and mood (0.67). 
Some evidence of sensitivity. Allow 20 mins. 
Extensively validated with carers of people with learning disabilities and 
epilepsy. Internal consistency mean alpha is 0.92 (range for sub-scales: 
0.72-0.91). Mean alpha if item deleted also 0.92. Test-retest reliability 
is 0.86. Pure factorial structure. Allow 10 mins. 
Scale in development. For use in appraisal of outcomes resulting from 
contact with services, and to assist in ‘purchasing’ decisions. Likely to 
be general but may include epilepsy as an item. Expected to be around 
12 items and take 10 mins to complete. 
the treatment of epilepsy. Often the seizures are the 
sole focus. The importance of the clinical history, of 
diagnostic evaluation, and of ongoing monitoring of 
seizure events is self-evident in epilepsy work. How- 
ever, in this particular population accurate identifica- 
tion, differential diagnosis and reliable recording of 
seizure frequency can prove very problematic. Fur- 
thermore, the patient is often unable, due to intel- 
lectual and/or communication difficulties, to describe 
their symptoms and clinicians have to rely on carer 
observation and report (see Espie and Paul2 for a re- 
view). 
A second area for measurement relates to 
antiepileptic drugs (AEDs). Treatment with AEDs is 
the mainstay of clinical practice. It is generally the 
effectiveness of these drugs which is being evaiuated 
in the clinic. Concerns about compliance and about 
frequency of side-effects often arise, and these have 
to be quantified and weighed in balance against evi- 
dence of benefit. Importantly, other drugs may affect 
seizure thresholds, and the genera1 functioning of the 
individual. Prescription of neuroleptic medication, for 
example, in people with learning disabilities, is not 
uncommon3. 
Allied to monitoring drug side-effects, in particular 
that of drowsiness, is the appraisal of cognitivefunc- 
tions. There is a long history of neuropsychological 
expertise associated with both research and practice in 
epilepsy (see, for example, Bennett4). It is important 
to recognize that neuropsychological functions may 
be affected directly by seizure activity, by drug ef- 
fects (as mentioned) by variation in arousal state’, by 
environmental conditions2, by circadian factors (Es- 
pie et al in press), and possibly also by care practices. 
There is some literature on the association between 
behaviourlpsychopathology and epilepsy in people 
with learning disabi1ities2y”t’. The ‘epilepsy plus’ 
presentation is often comp1ex’2 and an understand- 
ing of the interrelationships between various clinical 
concerns may be critical to effective management. 
Non-epileptic seizures and self-induced seizures are 
relatively common in people with learning disabili- 
ties, and in most cases occur in people who also have 
genuine epileptic attacks’. 
Although epilepsy can be regarded as a symp- 
tqmatic disorder, or even as purely a symptom of 
an underlying neurological disturbance, nevertheless, 
it is often associated with considerable impact upon 
socialfunctioning. In people with learning disabilities 
constraints upon independence and skill development 
are, of course, inevitable by virtue of the individual’s 
condition. However, there is some evidence of ad- 
ditional handicapping where epilepsy presents as a 
co-morbid problem lo* I’. For example, the presenta- 
tion of epilepsy may become a barrier to community 
placement. The genera1 literature on epilepsy attests 
the impact of a diagnosis of epilepsy upon employ- 
ment and leisure opportunityt3. 
The majority of people with learning disabilities 
have family or staff carers who are intimately in- 
volved with their lives. Curer functioning, there- 
fore, becomes a concern. The clinician normally 
works through the carer and will often recognize that 
epilepsy is a family prob1em14. The carer’s ability to 
sustain the care role is crucial to the patient’s well- 
being, and yet it may be difficult for carers to achieve 
a healthy balance between responsibility and indepen- 
dence. Carers do experience strain, and family carers 
in particular may be prone to experience clinically 
significant levels of anxiety and depression15. 
A considerable amount is known about attitudes 
which people (both sufferers and society) have to- 
wards epilepsy. In particular, social stigma has 
been researched16s17 and attributional states may 
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make an important contribution towards coping with 
epilepsy . ‘& I9 In the field of learning disabilities, peo- 
ple’s level of knowledge about the condition and their 
views and values have not, to our knowledge, been 
formally reported. Nevertheless, this seems an impor- 
tant area for development. 
Similarly, motivation has received scant attention in 
spite of the fact that factors such as regular attendance 
at clinics and compliance in taking medication may 
be critical to achieve optimaI con& over seizures. 
In learning disabilities, we are of course concerned 
also with the motivation and compliance of carers, 
and this would seem to be an appropriate domain for 
measures to be developed. Treatment compliance is 
regarded as a critical ingredient in good therapeutic 
outcome20. 
Finally, there has been considerable interest in re- 
cent years in ‘qualiry of fife’. This is included as a 
separate category, primarily in recognition of the fact 
that some measures attempt to span a number of the 
domains mentioned above. Thus, we may regard qual- 
ity of life as a construct which reflects a number of 
facets of well-being. There are some published scales 
for measuring quality of life”-23; however, it is only 
in recent times that specific attention has been paid to 
quality-of-life assessment in the population of people 
who have epilepsy and learning disabilitiesr5. 
WHAT MEASUREMENT CRITERIA SHOULD 
BE APPLIED? 
It is nut the purpose of this paper to review in any 
detail psychometric properties of scales, However, it 
may be helpful to describe the key qualities which 
measurement instruments should demonstrate. These 
are validity, reliability, sensitivity and practicability. 
Validity is the most important property since it re- 
lates to the question: Are we measuring what we 
think we’re measuring? However reliable, sensitive 
and user-friendly a scale may be. if it is not valid for 
the purpose of which it is intended, it is of no value 
at all. Validity places the emphasis on whar is being 
measured and in particular, whether the instrument is 
measuring what the investigator intends it to measure. 
Most classification systems describe four types of va- 
lidity, i.e. content validity, criterion-related validity, 
construct validity and face validity. Content validity 
refers to the representativeness or sampling adequacy 
of the content of the measuring instrument. A scale 
should comprise items which can be judged as rep- 
resentative of its purpose. Criterion-related validity 
is where a scale is compared with external variables 
(criteria) which are known to measure the attribute 
under study. The higher the correlation between the 
scale and the criterion, the better the validity. Con- 
struct validity relates to the meaning of the test. In 
other words it is more preoccupied with theoretical 
constructs. Construct validation is not simply a ques- 
tion of validating a test but of validating a theory be- 
hind a test. Finally face validity, as the term implies, 
relates to the instrument ‘looking right’ to potential 
users. Its purposes and uses should be explicit and 
overtly obvious. 
Reliability has synonyms such as dependability, 
stability, consistency, predictabiIity and accuracy. 
Measures are more or less variable from occasion to 
occasion and in this sense are either stable, and rel- 
atively predictable, or they are unstable, and relative 
unpredictable; they are consistent or not consistent. 
If they are reliable we can depend upon them and 
if they are unreliable we cannot. Typical questions 
about reliability are: If we use this instrument again 
will we get the same or similar results? How much 
measurement error is there in the scale? Test-retest 
reliability is when the same scale is administered on 
two separate occasions. Interrater reliability is used to 
check reliabiiity of scores across observers. Internal 
consistency is a way of estimating reliability from the 
variances and covariances of all the items with each 
other. An extension of internal consistency is item 
deletion which systematically assesses the stability of 
a scale with items removed. 
In addition to validity and reliability, a measure 
should demonstrate sensirivify; that is it should be 
capable of discriminating, in a consistent manner, 
between individuals, say with different levels of 
symptomatology, and within the individual to detect 
change over time, say in response to treatment. If a 
measure is not sensitive it may fail to detect genuine 
improvement or deterioration. Clearly it is desirable 
that a scale should be sensitive. However, there can 
be problems where only two measurements are taken, 
e.g. before and after treatment, since a sensitive mea- 
sure may be quite reactive to particular circumstances, 
such as the day on which it was completed. Multiple 
assessments of change can be useful with several val- 
ues taken in both baseline and treatment phases. Also 
immediate/marked change after intervention tends to 
most reliably indicate the efficacy of the treatment. 
Finally, it is critically important that any measure 
used is practicable. It would be possible to devise 
measures and procedures which are sophisticated in 
psychometric terms but which are simply too compli- 
cated for people to administer or which take up too 
much time in practice. It is essential to take into ac- 
count the genuine constraints of the setting in which 
measurements take place. These include the time re- 
quired for each assessment, he numbers of people to 
be assessed, the effects of fatigue, the readability of 
the scales and the compliance both of staff and of 
patients and their carers with the procedures. 
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Having considered the domains of measurement and 
the criteria which should be applied to specific assess- 
ments, this section will now review the range of out- 
come measures in current use. These are summarized 
in Table 1, where information on scale ‘qualities’ is 
also presented. 
Measures relating to seizures 
The International League Against Epilepsy (ILAE) 
classification is accepted as the standard system of 
classification and terminology24. Nevertheless, there 
are recognized difficulties in interobserver agreement, 
even when standard criteria are applied2vZ5. Clinicians 
very seldom observe seizures at first hand and gener- 
ally have to rely on a verbal or a written report. The 
Concerted Action Family Data protocol is a document 
produced for a Europe-wide project on the genetics of 
epilepsy. It seeks to provide clear written recordings 
of actual seizures and investigations for the individual 
and other family members (F. Elmsley, pers. comm.). 
These can be coded against the ILAE classification 
and confidence in reaching the diagnostic decision 
can be measured on a scale of l-5. There may be 
advantages to this approach over the traditional use 
of seizure charts, which are widely produced by clin- 
ical departments and by the pharmaceutical industry. 
Such charts have the advantage of being very quick to 
complete and to give ‘a week at a glance’ overview. 
However, they may commit inexperienced observers 
to differentiate between seizure types, a distinction 
which is known to be difficult, even amongst expe- 
rienced clinicians. Furthermore, some charts refer to 
‘major’ and ‘minor’ fits; a rather arbitrary dichotomy. 
A considerable problem for most recording systems 
is that certain types of fits, e.g. absence seizures and 
myoclonic seizures are difficult to detect and their 
true frequency difficult to record. Repeated absence 
seizures can be usefully assessed by continuous moni- 
toring (e.g. the St. Piers, Lingfield Monolog Monitor). 
Pau126 and Espie and Paul2 describe the use of 
seizure diaries which have a similar philosophy to the 
Concerted Action Protocol. Behavioural descriptors 
are written for each of the common seizure presenta- 
tions exhibited by an individual which then requires 
carers only to enter a code letter and time at each pre- 
sentation of the seizure, rather than having to make 
a classification decision. The seizure diaries can then 
be presented to clinicians and are more likely to pro- 
vide the critical information required for diagnostic 
and treatment purposes. Behavioural descriptors can 
be improved by interviewing several eye witnesses in 
order to agree criterion features. 
Direct observation/recording of seizures is, of 
course, technically possible, e.g. video telemetry, 
observer data on hand-held computers’. However, 
seizure events often prove elusive. For example, Es- 
pie and Paul2 captured only 11 events in 1388 ran- 
dom videotape samples of 28 people with refractory 
epilepsy. Betts advocates the use of video-recording 
by means of a video-camera lending system to max- 
imize this assessment processzs. Video records are 
particularly helpful in the differential diagnosis of 
epileptic and non-epileptic seizures. Behaviour an- 
alytical methods are also widely used to identify 
antecedent triggers for seizures, to establish con- 
texts/times when they are most likely to occur and 
to determine the effects of the seizures within the en- 
vironment in which they occur. Such analyses can be 
readily incorporated into seizure -diaries. Clearly it is 
valuable to have as much descriptive information as 
possible on seizure presentation since this can permit 
a broader approach to intervention. 
The Liverpool Seizure Severity Scale (LSSS)2’ was 
originally designed for self-completion by adults in 
AED trials. It has recently been adapted for comple- 
tion by carers of children with learning disabilities 
and has been used in a randomized clinical trial of a 
novel AED in the treatment of Lennox-Gastaut Syn- 
drome. The LSSS appears to have good validity and 
reliability. Apart from a recently published paper by 
Carpay eta1 , 27 this is probably the only severity scale 
which would be of value with this particular patient 
population. To our knowledge, the Chalfont Seizure 
Severity Scale has not been adapted for use with 
learning disabilities. Seizure severity is, of course, 
a difficult concept to define. In the LSSS, severity is 
measured principally in relation to the ictal and post- 
ictal effects of the seizures. It must be recognized that 
a physician, carer, and a patient may have different 
views concerning the severity of the patient’s pattern 
of seizures. Each perspective is valid and may be 
valuable. Similarly, the extent to which seizures are 
intrusive upon lifestyle crucially depends upon that 
lifestyle. For example, one seizure per month experi- 
enced by someone who is working may be extremely 
disruptive, and an individual with seizures every day 
may adapt to this expectation. 
Measures relating to drugs 
People with learning disabilities may not be able to 
tell clinicians about side-effects experienced while 
taking a drug. Also, it may be difficult to differentiate 
between the effects of a particular drug and symptoms 
which have already been there for quite some time. 
Attention to the history is important before conclud- 
344 C. A. Espie et a/ 
ing how to attribute them. There is a natural tendency 
to wish to find explanations of symptoms. Neverthe- 
less, it is important to do so with some accuracy of 
prediction. There is also the difficulty of distinguish- 
ing drug effects from epilepsy effects and this is usu- 
ally dependent upon a judgement made by the per- 
son completing the scale, or conducting the interview. 
Discontinuing medications can also be problematicZ8 
and may confound measurement. 
Drug profiles normally include lists of known side- 
effects, and these can provide a reasonable check 
list on events which may be predictable. Although 
there may be a risk of putting words into people’s 
mouths, with this patient group it is very important 
to be proactive in seeking information due to inherent 
communication problems. Much may depend on the 
relationship of the carer to the person with learning 
disabilities, how long they have known the individ- 
ual, and the consistency with which they attend the 
clinic. Some doctors also find that circulated lists pro- 
duced by pharmacists can be very helpful. The ma- 
jority of AEDs have recognized specific side-effects 
(e.g. Lamotrigine rash) rather than there being a core 
data set which would apply to all AEDs. Some symp- 
tomatic side-effects are clearly visible whereas oth- 
ers, such as double vision, are experiential and rely 
entirely upon self-report. It is the experiential side- 
effects which are less likely to be detected in the 
learning disability population. The development of 
materials like ‘widget symbols’* may in time permit 
greater free responding for people with communica- 
tion difficulties. 
Behaviour change, observable to a familiar carer, 
may also be an indication of drug effects”*‘9*30. 
Some of these changes can be quite subtle. Further- 
more, symptoms of somnolence and passivity may 
be more readily accepted as tolerable by carers than 
symptoms of irritability and upset. This is a concern 
since there may be marked interruption of function- 
ing in such cases. Table 1 mentions several scales, 
produced by the pharmaceutical industry which help 
to monitor signs and symptoms. The Adverse Events 
Profile3t has been developed as a patient-perceived 
side-effects profile and has recently been adapted for 
completion by a parent or carer. 
There are objective tests, developed within exper- 
imental paradigms, for measuring vigilance and at- 
tention; which is a marker for a person’s ability to 
process information. In one major study, the Leeds 
Psychomotor Test was adapted to a very simple two- 
choice reaction-time test, where subjects had to press 
a large button pad to extinguish a signal light (Espie et 
al unpubl.). A number of departments use such psy- 
chomotor tests to monitor drowsiness in people with 
epilepsy who are on AEDs. However, many of the 
available test formats are too complicated for people 
with learning disabilities. 
Measures of cognitive function 
As Table 1 indicates, there are many published and 
widely used neuropsychological tests with good psy- 
chometric properties, e.g. the Wechsler Adult In- 
telligence Scale-Revised (WAIS-R)32, the Wechsler 
Memory Scale-Revised (WMS-R)33, the Rivermead 
Behavioural Memory Test (RBMT)34 and the British 
Ability Scales (BAS) 35 However, the majority of . 
these have not been standardized on people with 
learning disabilities and will prove insensitive to mea- 
surement at the lower end of their scales. The Wech- 
sler scales are amongst the most commonly used in 
departments. Some tests used to illustrate the effect 
of sub-clinical epileptic discharges in right and left 
hemisphere tasks have been computerized and are op- 
erated by the use of a touch-sensitive screen. An ex- 
ample of such a test is derived from the Corsi block 
test36. The test, time-linked to EEG, allows com- 
ment on the location of an epileptic focus in cases 
where this cannot be detected by more standard pro- 
cedures3’. The FePsy38 is another computerized bat- 
tery of cognitive function tests comprising sub-tests 
on vigilance, reaction time and psychomotor func- 
tion. Extensive normative datasets are available for 
the FePsy, including some data from children with 
special educational needs. However, both the Corsi 
tests and the FePsy are probably best restricted to 
more able groups of people within the population of 
those with learning disabilities. 
A neurotoxicity scale to assess the effects of cog- 
nitive functioning on daily activities has been devel- 
oped . 39.40 Simple analogue ratings where target func- 
tions such as ‘concentration’ or ‘tiredness’ are scored 
along 10 cm lines can act as a gauge of perceived 
function. Such measures have the advantage of being 
completed very quickly, and have face validity but at 
present lack any other formal psychometric justifica- 
tion. 
Behavioural state analysis4’*42 is a system which 
ascribes arousal status to observed behaviour. The 
optimal state of ‘awake-active-alert’ implies that the 
individual is actively engaged with his/her environ- 
ment. Criteria have been drawn up for this and other 
behaviour states, e.g. awake-inactive-alert, drowsy, 
dazed, sleep. However, there is some debate in the 
literature as to the reliability of such measurement43. 
These studies have not been conducted specifically on 
people with epilepsy; however, Espie er al have done 
so recently (Espie et al unpubl.). The principal prob- 
*Widget Software, 102 Radford Road, Leamington Spa CV31 ILS. 
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lem with behaviour-state analysis is that it requires 
trained observers to observe individuals over lengthy 
time periods. It is more an education and training 
methodology than one for treatment-outcome prac- 
tice. 
Measures of behavioural adjustment 
A number of useful measures of behaviour and psy- 
chopathology are reported in Table 1. The Psy- 
chopathology Inventory for Mentally Retarded Adults 
(PIMRA)85 may be used as a structured interview to 
identify formal psychiatric disorders in people with 
learning disabilities. The PIMRA has been avail- 
able for some years. More recently the Psychiatric 
Assessment Schedule for Adults with Developmen- 
tal Disability (PASSAD) has become the ‘gold stan- 
dard’ and is sometimes used in clinical trials as 
a screening measure, particularly to identify psy- 
chosis (Hester Adrian Research Centre, Manchester, 
1994). More commonly, however, clinicians are in- 
terested in types of behavioural disorder and their 
severity. The Aberrant Behaviour Checklist (ABC)45 
may be particularly appropriate for use with people 
who have learning disabilities plus epilepsy since it 
was originally developed as an outcome measure for 
use in clinical trials. Similarly, the Psychosocial Be- 
haviour Scale (PBS)46 was designed specifically for 
people with learning disabilities and epilepsy, par- 
ticularly for more able individuals who present an- 
tisocial and attention-seeking behaviours. Both the 
ABC and the PBS have useful sub-scales and have 
published validity and reliability data. The Adap- 
tive Behavior Scales-Part Two4’ are commonly used 
in clinical practice and are useful, although they 
do not specifically relate to this co-morbid patient 
group. They can also be time-consuming to com- 
plete. Other measures include the Attention Deficit 
Disorder-Hyperactivity Questionnaire on which Es- 
pie and Paul have some unpublished data (translated 
from Boudreault et a148) and O’Brien’s SSBP postal 
questionnaires which are suitable for both children 
and adults and incorporates developmental assess- 
ment49y50. Recent extensive reviews of published be- 
havioural measures can be consulted for further in- 
formation5 l. 
A new scale has been developed for use in a trial of 
patients with Lennox-Gastaut Syndrome55. The start- 
ing point for the Epilepsy and Learning Disability 
Quality of Life Scale was a compilation of anecdotal 
information from experienced clinicians. The scale is 
completed by parents and has been used in a ma- 
jor European drug trial comprising 140 patients. It 
has 66 items comprising three sub-scales on seizure 
severity (adapted from the Liverpool adult version), 
behaviour (sleep, appetite, communication, alertness) 
and mood (irritability, cheerfulness etc.). The scale 
has been validated both by clinicians and carers and 
reliability data are satisfactory. Test-retest reliability 
on the mood sub-scale was not strong, but this is not 
surprising since mood does fluctuate more than be- 
havioural variables (see also later section on ‘global 
measures’). 
It is important to recognize that in clinical prac- 
tice many people do not use scales. They are too 
time-consuming either in administration or in terms 
of productive use of the data which they generate. 
Nevertheless, behavioural information should be ap- 
praised, particularly where specific problems are re- 
ported within the individual presentation. For clinical 
practice, Kerr recommends a simple visual analogue 
scale where up to five targets which drugs and the 
treatment of epilepsy might affect are agreed between 
carers and the clinician. Changes in these related to an 
agreed baseline can then be assessed. This approach 
represents the ultimate in validity for individual clin- 
ical work although it is not possible to collate data 
across subjects using this method. In practice, many 
clinicians have their own local measures for monitor- 
ing behavioural factors and some use measures which 
are supplied by the pharmaceutical industry. 
One of the difficulties in working with people with 
learning disabilities is the assessment of temperament 
and mood independently from behaviour. Neverthe- 
less, it does seem important to recognize underly- 
ing mood states and personality characteristics which 
may have a bearing upon presentation. The Psychoso- 
cial Behaviour Scale46 measures aspects of trait ten- 
dency, e.g. attention-seeking behaviour. The Zung 
Anxiety Scale has been adapted for use with people 
with mild learning disabilities56. 
Measures relating to social functioning 
The best-known scale in this domain is the Washing- 
ton Psychosocial Seizure Inventory (WPSD5’. How- 
ever, the WPSI loads very heavily on independent so- 
cial functions such as employment, driving, income, 
etc. and has limited validity, therefore, except for 
those people with mild/borderline learning disabili- 
ties. It also has a North American emphasis and psy- 
chometric limitations in that its scaling is generally 
in yes/no format which does not permit gauging of 
strength of emphasis. There is no means by which 
more important areas can be differentially weighted. 
Clark makes use of the WPSI-Professional Rating 
Scale which is a professionally completed short ver- 
sion, but again only for more able patients. 
The Vineland Adaptive Behaviour Scales (VABS)58 
can be recommended as a robust, descriptive measure 
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ule6* may be useful in assessing parental concerns in 
children with epilepsy. 
of social functioning. In particular, the expanded form 
of the VABS sub-scales on personal, daily living and 
community skills can be used for detailed descriptive 
purposes. They are less useful as outcome measure- 
ments because of their global nature. 
Other measures of social functioning include the 
Adaptive Behavior Scales-Part Two4’ and the Lid- 
combe Psychosocial Disability Scale59. The former 
is extensively used in North America and provides 
a comprehensive profile of personal and daily life 
functions, and the latter is Australian and is a brief 
assessment of social functioning for use with patients 
who have acquired brain damage. 
Once again, the most suitable measure will depend 
upon the measurement purpose. In research studies a 
standardized scale may be required to look at psy- 
chosocial outcome over the longer term. In clinical 
trials, which may last only relatively short periods of 
time, it is unlikely that global social functioning will 
demonstrate change. In these circumstances, and in 
routine clinical practice, more sensitive, specific mea- 
sures may need to be devised to reflect the particular 
goals of the intervention and the individual’s partic- 
ular circumstances. Some departments incorporate an 
index of social functioning within the interview pro- 
cess (e.g. O’Brien: Clinical History Questionnaire), 
also some syndrome-specific measures may be de- 
veloped which are sensitive to the specific social and 
functional sequelae of individual disorders (e.g. Rett 
Disorder6’). 
Measures relating to attitudes 
There is a sizeable literature on concepts such as 
stigma. However, little is known about how the per- 
son with learning disabilities feels, and is perceived 
by others, when they have epilepsy. Similarly, lit- 
tle is known about their knowledge and understand- 
ing of epilepsy itself. The Epilepsy Knowledge Pro- 
file (EKP)69 represent a recent attempt to develop 
measures in this latter area for people with epilepsy. 
More recently, the EKP (Personal Information) has 
been adapted for direct use with people with learning 
disabilities’O and the EKP (General Knowledge) has 
been used with carers of people with learning disabil- 
ities to assess their knowledge of the condition (Espie 
et al in press). 
Clearly, further work would be welcome in this 
field since attitudes can be powerful facilitators or 
inhibitors of therapeutic progress both directly (e.g. 
compliance with advice) and indirectly (e.g. per- 
ceived stigma). Also, mention was made earlier of 
attributional factors being important in the appraisal 
of what may (or may not) be side-effects of medica- 
tion. Similar attributional issues arise in the perceived 
associations between behaviour and seizures. 
Measures relating to motivation 
Measures relating to carer functioning 
Reference was made earlier to the fact that epilepsy in 
learning disabilities affects the family and/or the care 
system. The capacity of carers to cope is a very im- 
portant factor in clinical management of the individ- 
ual with epilepsy. Symptomatic rating scales of anx- 
iety and depression can be useful here, e.g. The Hos- 
pital Anxiety and Depression Scale (HADS)61, the 
Beck Depression Inventory (BDI)@, and the General 
Health Questionnaire (GHQ)63. The Index of Psycho- 
logical Well-being& can also be recommended as a 
very brief scale. 
Rather than assessing carer symptomatology, an- 
other approach is to measure the carer’s experience 
of strain and responsibility. Clark recommends the 
use of a Family Feelings Questionnaire which is a 
local modification of the Burden Inventory65. The 
concept of burden can be subdivided into objective 
burden and subjective burde#. The Caregiver Strain 
Index6’ was originally developed for carers of peo- 
ple who had experienced a CVA. It has the advantage 
of being relatively brief and may be readily adapted 
for this carer group. The Impact of Epilepsy Sched- 
All clinicians utilize some implicit measure of the 
individual’s or the carer’s motivation. These might 
be default patterns from attendance at clinics, com- 
pliance with advice in taking AEDs, etc. Everyone 
would agree that motivation is a crucial issue. Nev- 
ertheless, there are few measures of the concept. The 
results of clinical trials of AEDs inevitably represent 
the optimal situation. That is where subjects have re- 
mained in the study, have complied with the some- 
times rigorous schedule of repeated measurement and 
attendance at clinics, and have taken drugs in pre- 
scribed doses. The extent to which such results gen- 
eralize to the more heterogeneous clinical population 
is not guaranteed. Clearly, effort should be made to 
record motivation in some form and behavioural mea- 
sures such as attendance rates may be the most robust. 
Motivation may be measured in a more indirect 
way through scales such as the Rosenbaum Self- 
control Schedule (RSCS)“. Although this is a com- 
plex measure, which takes some time to complete, 
a shortened version has been developed comprising 
only six items ‘* The RSCS measures the individ- . 
ual’s tendency to internalize or externalize the locus 
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of control. In other words it is a measure of per- 
sonal resourcefulness. This could be a useful mea- 
sure for more able patients or for carers. There is 
some evidence that people with learning disabilities 
and epilepsy have an external locus of control orien- 
tation’ ’ . The Adolescent Coping Scale73 may also be 
useful with younger people for similar purposes. 
Global assessment measures (quality of life) 
There will always be tension between detailed, spe- 
cific measurement and measures which seek to take 
a global overview. The decision about which path 
to go down will be a pragmatic one, situationally 
determined and heavily influenced by the amount 
of time available. Formal research studies will gen- 
erally afford the opportunity for multiple measure- 
ments whereas clinical practice will be heavily time- 
constrained. Nevertheless, global measures will also 
be useful in research study since an integrated mea- 
sure may give a better picture of the variance within 
and between subjects, and reflect a true-life picture. 
This section of Table 1, therefore, summarizes those 
measures which could be considered global and re- 
flective of the concept of ‘quality of life’. 
The new scale for children with learning disabili- 
ties and epilepsy (ELDQOL)76 has already been dis- 
cussed, and appears to meet the criteria for global 
measurement. The Liverpool group have previously 
published quality-of-life assessment scales which are 
in widespread use in research and clinical practice74. 
These measures incorporate the LSSS mentioned ear- 
lier but also include assessment of the impact of 
epilepsy-adults and children75v76* life fulfilment77; 
stigma54; and AED side-effects (Baker, unpubl.). 
The Epilepsy Outcome Scale (EOS) (Espie et al 
in press) is another new scale which has been de- 
veloped specifically for use with adults with epilepsy 
and learning disabilities. This scale was derived from 
workshops held with family and staff carers of people 
with learning disabilities. Through an iterative pro- 
cess, items were selected which reflected their prin- 
cipal concerns in four main areas, i.e. concerns about 
seizures, drugs, injury and effects on day-to-day liv- 
ing. The EOS has been well validated and has very 
good psychometric properties making it potentially 
useful as a research tool. It also has the advantage of 
being quickly completed and being suitable for use in 
clinics. Further studies are underway to consider its 
sensitivity to measure change. 
A Health of the Nation Outcome Scale (HoNOS) 
specifically for use with people who have learning 
disabilities is currently being developed by a working 
group under the aegis of the Department of Health. 
This would be primarily for surveying and compar- 
ing large populations on clinical and social charac- 
teristics. It is not yet clear what content the HoNOS 
scale would have, although it is likely to be rela- 
tively brief and suitable for completion by any pro- 
fessional involved in care provision. It is to be hoped 
that epilepsy will be included as one dimension of 
outcome measurement. 
WHAT ARE THE CURRENT PRIORITIES FOR 
RESEARCH AND DEVELOPMENT? 
The authors would suggest five major priorities. First, 
it is clear from the review that relatively few scales 
have been adequately tested on people with learn- 
ing disabilities. The review identifies the extent to 
which available measures can be validly and reliably 
applied. Assumptions cannot be made concerning the 
psychometric properties of scales and their applicabil- 
ity to ‘new’ populations. The first priority, therefore, 
is for good-quality research on scale development to 
continue. A number of promising scales are emerging, 
for example, as global measures (Epilepsy Outcome 
Scale; Espie et al in press; ELDQOL7*). Also it will 
be critically important to demonstrate, through scien- 
tific study, that measures are capable of picking up 
real changes at follow-up. 
Secondly, measurement within learning disability is 
often more indirect than within general clinical prac- 
tice. Carers’ needs and concerns are likely to influ- 
ence the reporting of outcomes, and these may differ 
depending upon which carer you ask. It will be impor- 
tant to develop methodologies for comparing and cor- 
relating perceptions and perspectives on the patient’s 
epilepsy. Also, measurement of carer ‘coping’ may 
yield an important predictor variable. Furthermore, 
the patient’s own viewpoint should not be omitted by 
default. It may be more accessible than is generally 
thought. 
Thirdly, there are particular problems associated 
with the measurement of cognitive functioning in 
people with learning disabilities. Few neuropsycho- 
logical and psychomotor batteries have norms which 
extend into the range of even moderate learning dis- 
ability. Thus, there are ‘floor effects’ in measurement 
which severely curtail their applicability. Objective 
measures of attention and vigilance probably offer 
the most fruitful line for development here. Learning 
disability is generally defined in terms of both intel- 
lectual and social handicap. Scales for the appraisal 
of the latter appear more robust. 
Fourthly, there is still a considerable amount of 
work needing to be done on differential diagnosis in 
this population. Both neurophysiological and struc- 
tured behavioural data may be required to ascertain 
the clinical diagnosis with any reliability. Videotape 
evidence, real-time recording and ambulatory moni- 
toring should be further studied. The reliance on clin- 
ical judgement, albeit based on the comments of ex- 
perienced (but untrained) observers, is less than satis- 
factory. This is particularly the case given that patient 
self-report is usually a critical component of the inter- 
view in the epilepsy clinic, and this may be unavail- 
able to aid the clinician’s judgement. The ideal model 
is that of the ‘scientist-practitioner’ where hypotheses 
are raised and tested through the systematic collection 
of data relevant to a series of clinical questions. 
Finally, and related to the previous point, is the im- 
portance of developing methodologies for the assess- 
ment of ‘dual therapies’, i.e. pharmacotherapy plus 
psychological therapy. The high prevalence rate of 
non-epileptic seizures and of self-induced seizures 
in this population has clear implications for such a 
methodology. 
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